What is OSSIO?
OSSIO is at the forefront of orthopedic innovation, developing and commercializing its proprietary OSSIOfiber® technology. This unique material is designed to facilitate natural bone regeneration, offering an alternative to traditional metal implants by avoiding the need for permanent hardware. The company's product portfolio includes a range of solutions such as suture anchors, fixation nails, and hammertoe fixation systems, all engineered to enhance patient outcomes and satisfaction through a more integrated and effective healing process. OSSIO's commitment to advancing orthopedic care is evident in its focus on natural bone healing principles.
How much funding has OSSIO raised?
OSSIO has raised a total of $138.1M across 4 funding rounds:
Series A
$22M
Series C
$38.5M
Private Equity
$27.6M
Debt
$50M
Series A (2019): $22M, investors not publicly disclosed
Series C (2022): $38.5M led by MVM Partners
Private Equity (2024): $27.6M supported by OCV Partners, MVM Partners, Courage Capital Management, and Questa Capital
Debt (2026): $50M featuring Monroe Capital and Horizon Technology Finance
Key Investors in OSSIO
OCV Partners
OCV Partners is a venture capital firm based in Los Angeles that specializes in investing in companies with differentiated technologies in high-potential markets, particularly in sectors such as SaaS, FinTech, PropTech, and healthcare. The firm leverages its extensive experience as former founders to provide not just capital but also strategic support to help entrepreneurs create disruptive innovations that transform their industries.
MVM Partners
MVM Partners LLP invests in innovative healthcare companies, actively supporting businesses that enhance healthcare delivery through quality and cost-effective solutions. With teams based in Boston, London, and the San Francisco Bay Area, MVM's focus spans various sectors including medical technology, pharmaceuticals, and digital health.
Courage Capital Management
Courage Capital Management, founded in 1998, specializes in managing private funds for institutional investors and family offices with a focus on three investment strategies: Healthcare Investing, Music Rights Acquisitions, and Small Business Financing. The firm is led by experienced professionals, including founder Richard Patton and President Tom Milne, who bring extensive backgrounds in finance and investment management.
What's next for OSSIO?
With the recent major strategic investment and significant overall capital raised, OSSIO is poised to accelerate its development and commercialization efforts. The substantial enterprise-level funding suggests a strategic focus on scaling operations, expanding market reach, and potentially investing further in research and development to enhance its OSSIOfiber® technology. This financial backing will likely enable OSSIO to solidify its position as a leader in the orthopedic implant market, offering advanced solutions that prioritize natural bone healing and reduce the complications associated with permanent hardware.
See full OSSIO company page
